Pinnacle BIO Consulting launches BioOncology2004: Shifting Paradigms in Anticancer Therapeutics

April 26th 2004. With the recent FDA approval of several new, targeted anticancer therapies, and now new positive news from Genentech/OSI Pharmaceuticals candidate Tarceva-TM, it is clear that targeted therapies in Oncology are emerging as a new paradigm in anticancer strategy. The anticancer field is becoming quite extensive, with multiple targets and promising strategies in development today. At Pinnacle BIO Consulting, we have been immersed in the Oncology field, and have provided long-term strategic planning for many of the top Biotech companies in the United States and Europe. We have prepared a white paper focused on the BioOncology field, complete with analysis of the potential markets that will be part of the explosion of all stages of development of targeted anticancer therapies. This report is released on the heels of significant FDA approvals of novel, targeted anti-cancer therapeutics that will certainly change the dynamics of cancer treatment in the clinic. Thus, we offer this public "snap-shot" overview of the Oncology drug development field as of 2Q2004. This document is now available by request, free of charge at: http://www.pinnaclebio.com/biooncology2004.php 

Pinnacle BIO Consulting ( www.pinnaclebio.com ) is especially knowledgeable in areas of cancer signaling pathways and Oncology drug development, and provides clients with an objective, confidential, expert analysis of their anticancer drug and/or diagnostic development program. Through primary market research, in the form of interviews with thought leaders and/or practicing clinicians, we confidentially and objectively probe experts in the field regarding the biological requirements for a particular therapy, unmet therapeutic needs and barriers to enter the clinic, emerging competition, etc. When you combine our proactive strategy with our strong background in cancer etiology and current knowledge of the field, as well as many years of experience in strategy and planning for the pharmaceutical and biotech industries, Pinnacle BIO Consulting emerges as the prime candidate for anticancer drug development strategy and planning needs. 

A typical project could be focused on any of the following: Understanding the market size and share that a particular pipeline candidate is likely to achieve; Defining genotypic requirements for target patient populations that would be most likely to benefit from a specific therapy; Planning of clinical trial programs (defining patient and investigatory arm selection) so as to ensure maximum efficacy and benefit from your drug candidate; etc., customized to meet our client's specific needs.